Trial Profile
Randomized Phase II Study of Gemcitabine Plus Z-360 in Metastatic Pancreatic Adenocarcinoma Compared With Gemcitabine Plus Placebo ( ZIPANG Study )
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Z 360 (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms ZIPANG
- Sponsors Zeria
- 01 Aug 2017 Primary endpoint (Overall Survival) has not been met as per the results published in the Cancer Chemotherapy and Pharmacology
- 01 Aug 2017 Results (data cut-off date November 30, 2015) published in the Cancer Chemotherapy and Pharmacology
- 29 Jun 2017 Status changed from active, no longer recruiting to completed.